Xykaa PLUS Uses
Is this medication very expensive?
sponsored
Uses
Dosage
Side effects
Pregnancy
Overdose
Actions

Consists of Caffeine, Chlorpheniramine, Paracetamol, Phenylephrine

What is Caffeine (Xykaa PLUS)?

Caffeine (Xykaa PLUS) is a central nervous system stimulant. It works by stimulating the brain. Caffeine (Xykaa PLUS) is found naturally in foods and beverages such as coffee, tea, colas, energy and chocolate. Botanical sources of Caffeine (Xykaa PLUS) include kola nuts, guarana, and yerba mate. Caffeine (Xykaa PLUS) is also available in prescription and non-prescription medications.

Caffeine (Xykaa PLUS) is used to restore mental alertness or wakefulness during fatigue or drowsiness. Caffeine (Xykaa PLUS) is also found in some headache and migraine medications, in certain dietary supplements used for weight loss, and in many popular energy drinks.

Caffeine (Xykaa PLUS) (Caffeine (Xykaa PLUS)) is available by prescription only. It is used for short-term treatment of neonatal apnea (breathing problems).

Caffeine (Xykaa PLUS) may also be used for other conditions as determined by your health care provider.

Caffeine (Xykaa PLUS) indications

sponsored

Caffeine (Xykaa PLUS) and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe Caffeine (Xykaa PLUS) and other analeptics should not be used in these conditions and recommend other supportive therapy.

How should I use Caffeine (Xykaa PLUS)?

Use Caffeine (Xykaa PLUS) as directed by your health care provider. If the medication is OTC, check the label on the bottle for the exact dosing instructions. If you have any questions about the use of an OTC medication, ask your pharmacist.

Ask your health care provider any questions you may have about how to use Caffeine (Xykaa PLUS).

Uses of Caffeine (Xykaa PLUS) in details

sponsored

Use: Labeled Indications

Caffeine (Xykaa PLUS): Treatment of idiopathic apnea of prematurity

Caffeine (Xykaa PLUS) and sodium benzoate: See Off-Label uses.

Caffeine (Xykaa PLUS) [OTC labeling]: Restore mental alertness or wakefulness when experiencing fatigue

Off Label Uses

Augmentation of seizure induction during electroconvulsive therapy (Caffeine (Xykaa PLUS) and sodium benzoate)

Data from a randomized, double blind study as well as a few unblinded studies support the use of Caffeine (Xykaa PLUS)/sodium benzoate in the treatment of augmentation of seizure induction during electroconvulsive therapy (ECT).

Caffeine (Xykaa PLUS) description

A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine (Xykaa PLUS)'s most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of Caffeine (Xykaa PLUS) have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [PubChem]

Caffeine (Xykaa PLUS) dosage

sponsored

Usual Adult Dose for Drowsiness:

100 to 200 mg orally not more often than every 3 to 4 hours.

For occasional use only.

Not intended for use as a substitute for sleep.

Limit the use of Caffeine (Xykaa PLUS) containing medications, foods, or beverages while taking this product because too much Caffeine (Xykaa PLUS) may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.

Usual Pediatric Dose for Drowsiness:

>= 12 years: 100 to 200 mg not more often than every 3 to 4 hours.

For occasional use only.

Not intended for use as a substitute for sleep.

Limit the use of Caffeine (Xykaa PLUS) containing medications, foods, or beverages while taking this product because too much Caffeine (Xykaa PLUS) may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.

Usual Pediatric Dose for Apnea of Prematurity:

For short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.

Prior to initiation of Caffeine (Xykaa PLUS), baseline serum levels of Caffeine (Xykaa PLUS) should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to Caffeine (Xykaa PLUS). Likewise, baseline serum levels of Caffeine (Xykaa PLUS) should be measured in infants born to mothers who consumed Caffeine (Xykaa PLUS) prior to delivery, since Caffeine (Xykaa PLUS) readily crosses the placenta.

Loading Dose: 20 mg/kg Caffeine (Xykaa PLUS) intravenous (over 30 minutes) once

Maintenance Dose: 5 mg/kg Caffeine (Xykaa PLUS) intravenous (over 10 minutes) or orally every 24 hours.

Note: The dose of Caffeine (Xykaa PLUS) base is one-half the dose when expressed as Caffeine (Xykaa PLUS) (e.g., 20 mg of Caffeine (Xykaa PLUS) is equivalent to 10 mg of Caffeine (Xykaa PLUS) base).

Serum concentrations of Caffeine (Xykaa PLUS) may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.

Apnea of prematurity is a diagnosis of exclusion. Other causes of apnea (e.g., central nervous system disorders, primary lung disease, anemia, sepsis, metabolic disturbances, cardiovascular abnormalities, or obstructive apnea) should be ruled out or properly treated prior to initiation of Caffeine (Xykaa PLUS).

Caffeine (Xykaa PLUS) should be used with caution in infants with seizure disorders or cardiovascular disease.

The duration of treatment of apnea of prematurity in the placebo-controlled trial was limited to 10 to 12 days. The safety and efficacy of Caffeine (Xykaa PLUS) for longer periods of treatment have not been established.

Caffeine (Xykaa PLUS) interactions

See also:
What other drugs will affect Caffeine (Xykaa PLUS)?

sponsored

Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination

Adenosine: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving Caffeine (Xykaa PLUS). Discontinue Caffeine (Xykaa PLUS) in advance of scheduled diagnostic use of adenosine whenever possible. Consider therapy modification

Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Monitor therapy

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy

Bromperidol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may decrease the absorption of Bromperidol. Monitor therapy

BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Monitor therapy

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy

Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy

CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification

CYP1A2 Inducers (Moderate): May decrease the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

CYP1A2 Inhibitors (Strong): May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

Doxofylline: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Doxofylline. Avoid combination

Esketamine: May enhance the hypertensive effect of CNS Stimulants. Monitor therapy

Formoterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Formoterol. Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy

Indacaterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Indacaterol. Monitor therapy

Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification

Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification

Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification

Lithium: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may decrease the serum concentration of Lithium. Monitor therapy

Norfloxacin: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

Olodaterol: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may enhance the hypokalemic effect of Olodaterol. Monitor therapy

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification

Pipemidic Acid: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

Regadenoson: Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using Caffeine (Xykaa PLUS) or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Consider therapy modification

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy

Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. Monitor therapy

Stiripentol: May increase the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Avoid combination

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy

TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Consider therapy modification

Tobacco (Smoked): May decrease the serum concentration of Caffeine (Xykaa PLUS) and Caffeine (Xykaa PLUS) Containing Products. Monitor therapy

Caffeine (Xykaa PLUS) side effects

See also:
What are the possible side effects of Caffeine (Xykaa PLUS)?

Cardiovascular

Tachycardia; extrasystoles; palpitations; other cardiac arrhythmias.

CNS

Insomnia; restlessness; excitement; nervousness; tinnitus; scintillating scotoma; muscular tremor; headache; lightheadedness.

Dermatologic

Urticaria; rash, dry skin, skin breakdown (Caffeine (Xykaa PLUS)).

EENT

Retinopathy of prematurity (Caffeine (Xykaa PLUS)).

GI

Vomiting; nausea; diarrhea; stomach pain; necrotizing enterocolitis, gastritis, GI hemorrhage (Caffeine (Xykaa PLUS)).

Genitourinary

Diuresis; kidney failure (Caffeine (Xykaa PLUS)).

Hematologic

Disseminated intravascular coagulation (Caffeine (Xykaa PLUS)).

Metabolic

Hyperglycemia; acidosis (Caffeine (Xykaa PLUS)).

Respiratory

Dyspnea, lung edema (Caffeine (Xykaa PLUS)).

Miscellaneous

Hypersensitivity (eg, dermatitis, rhinitis, bronchial asthma); feeding intolerance, sepsis, accidental injury, hemorrhage, cerebral hemorrhage (Caffeine (Xykaa PLUS)).

Caffeine (Xykaa PLUS) contraindications

See also:
What is the most important information I should know about Caffeine (Xykaa PLUS)?

Caffeine (Xykaa PLUS) should not be given to a child who has had an allergic reaction to it in the past.

Before using Caffeine (Xykaa PLUS), tell the doctor if your child is allergic to any drugs, or has a seizure disorder, heart disease, kidney disease, liver disease, or high or low blood sugar.

Do not use the medication for longer than 12 days without the advice of your child's doctor.

Each bottle of Caffeine (Xykaa PLUS) is for one use only, even if your child does not use the entire bottle for a single dose. Throw away any medication left over in the bottle after measuring your child's dose.

Call your doctor if the child's breathing symptoms do not improve after using Caffeine (Xykaa PLUS).

To be sure Caffeine (Xykaa PLUS) is helping your child's condition, the child's blood will need to be tested on a regular basis. Do not miss any scheduled appointments.

What is Chlorpheniramine (Xykaa PLUS)?

Chlorpheniramine (Xykaa PLUS) is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Chlorpheniramine (Xykaa PLUS) is used to treat runny nose, sneezing, itching, and watery eyes caused by allergies, the common cold, or the flu.

Chlorpheniramine (Xykaa PLUS) may also be used for purposes not listed in this medication guide.

Chlorpheniramine (Xykaa PLUS) indications

this medicine is indicated for symptomatic control of all allergic conditions responsive to antihistamines, including hay fever, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites.

Also indicated for the symptomatic relief of itch associated with chickenpox

How should I use Chlorpheniramine (Xykaa PLUS)?

Use Chlorpheniramine (Xykaa PLUS) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Chlorpheniramine (Xykaa PLUS).

Uses of Chlorpheniramine (Xykaa PLUS) in details

Use: Labeled Indications

Allergic symptoms, allergic rhinitis, urticaria, pruritus: Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria, pruritus

Off Label Uses

Motion sickness

Data from a limited number of patients studied suggests that Chlorpheniramine (Xykaa PLUS) may be beneficial in the treatment of motion sickness. Additional data may be necessary to further define its role in this condition.

Chlorpheniramine (Xykaa PLUS) description

An alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used in the treatment of several disorders including asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.

Chlorpheniramine (Xykaa PLUS) dosage

Chlorpheniramine (Xykaa PLUS) Dosage

Generic name: Chlorpheniramine (Xykaa PLUS) MALEATE 4mg

Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

take every 4 to 6 hours, not more than 6 doses in 24 hours

adults and children 12 years of age and over 1 tablet (4 mg)
children 6 to under 12 years of age 1/2 tablet (2 mg)
children 4 to under 6 years of age

do not use unless

directed by a doctor
children under 4 years of age do not use

More about Chlorpheniramine (Xykaa PLUS) (Chlorpheniramine (Xykaa PLUS))

Consumer resources

Professional resources

Related treatment guides

Chlorpheniramine (Xykaa PLUS) interactions

See also:
What other drugs will affect Chlorpheniramine (Xykaa PLUS)?

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.

Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray), antispasmodics (e.g., atropine, belladonna alkaloids), drugs for Parkinson's disease (e.g., anticholinergics such as benztropine, trihexyphenidyl), scopolamine, tricyclic antidepressants (e.g., amitriptyline).

Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as: certain antihistamines (e.g., diphenhydramine), anti-seizure drugs (e.g., carbamazepine), medicine for sleep or anxiety (e.g., alprazolam, diazepam, zolpidem), muscle relaxants, narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., chlorpromazine, risperidone, amitriptyline, trazodone). Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain drowsiness-causing ingredients. Ask your pharmacist about the safe use of those products.

Chlorpheniramine (Xykaa PLUS) is very similar to dexchlorpheniramine. Do not use medications containing dexchlorpheniramine while using Chlorpheniramine (Xykaa PLUS).

This medication may interfere with certain laboratory tests (including allergy skin testing), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.

Chlorpheniramine (Xykaa PLUS) side effects

See also:
What are the possible side effects of Chlorpheniramine (Xykaa PLUS)?

Applies to Chlorpheniramine (Xykaa PLUS): capsules, controlled-release capsules, suspension drops, sustained-release capsules, syrup, tablets

Other dosage forms:

Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; nervousness or anxiety; trouble sleeping; upset stomach; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur while taking Chlorpheniramine (Xykaa PLUS) (the active ingredient contained in Chlorpheniramine (Xykaa PLUS) (Allergy))

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; hallucinations; seizures; severe dizziness, lightheadedness, or headache; tremor; trouble sleeping; vision changes.

Chlorpheniramine (Xykaa PLUS) contraindications

See also:
What is the most important information I should know about Chlorpheniramine (Xykaa PLUS)?

Hypersensitivity to Chlorpheniramine (Xykaa PLUS) maleate or any component of the formulation; narrow-angle glaucoma; bladder neck obstruction; symptomatic prostate hypertrophy; during acute asthmatic attacks; stenosing peptic ulcer; pyloroduodenal obstruction. Avoid use in premature and term newborns due to possible association with SIDS.

OTC labeling: When used for self-medication, do not use to make a child sleep

What is Paracetamol (Xykaa PLUS)?

Paracetamol (Xykaa PLUS) (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of Paracetamol (Xykaa PLUS) of is not known.

Paracetamol (Xykaa PLUS) is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.

Paracetamol (Xykaa PLUS) may also be used for other purposes not listed in this medication guide.

Paracetamol (Xykaa PLUS) indications

For systemic use of Paracetamol (Xykaa PLUS) Sante Naturelle: prevention and treatment of hypo- and avitaminosis of vitamin C; providing increased need for vitamin C during growth, pregnancy, lactation, with heavy loads, fatigue and during recovery after prolonged severe illness; in winter with an increased risk of infectious diseases.

For intravaginal use: chronic or recurrent vaginitis (bacterial vaginosis, nonspecific vaginitis) caused by the anaerobic flora (due to changes in pH of the vagina) in order to normalize disturbed vaginal microflora.

How should I use Paracetamol (Xykaa PLUS)?

Use Paracetamol (Xykaa PLUS) exactly as directed on the label, or as prescribed by your doctor.

Do not use more of this medication than is recommended. An overdose of Paracetamol (Xykaa PLUS) can cause serious harm. The maximum amount for adults is 1 gram (1000 mg) per dose and 4 grams (4000 mg) per day. Using more Paracetamol (Xykaa PLUS) could cause damage to your liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking Paracetamol (Xykaa PLUS) and never use more than 2 grams (2000 mg) per day. If you are treating a child, use a pediatric form of Paracetamol (Xykaa PLUS). Carefully follow the dosing directions on the medicine label. Do not give the medication to a child younger than 2 years old without the advice of a doctor.

Measure the liquid form of Paracetamol (Xykaa PLUS) with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. You may need to shake the liquid before each use. Follow the directions on the medicine label.

The Paracetamol (Xykaa PLUS) chewable tablet must be chewed thoroughly before you swallow it.

Make sure your hands are dry when handling the Paracetamol (Xykaa PLUS) disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.

To use the Paracetamol (Xykaa PLUS) effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.

Do not take a Paracetamol (Xykaa PLUS) rectal suppository by mouth. It is for use only in your rectum. Wash your hands before and after inserting the suppository.

Try to empty your bowel and bladder just before using the Paracetamol (Xykaa PLUS) suppository. Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands.

For best results from the suppository, lie down and insert the suppository pointed tip first into the rectum. Hold in the suppository for a few minutes. It will melt quickly once inserted and you should feel little or no discomfort while holding it in. Avoid using the bathroom just after inserting the suppository.

Stop using Paracetamol (Xykaa PLUS) and call your doctor if:

Urine glucose tests may produce false results while you are taking Paracetamol (Xykaa PLUS). Talk to your doctor if you are diabetic and you notice changes in your glucose levels during treatment.

Store Paracetamol (Xykaa PLUS) at room temperature away from heat and moisture. The rectal suppositories can be stored at room temperature or in the refrigerator.

Uses of Paracetamol (Xykaa PLUS) in details

This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.

How to use Paracetamol (Xykaa PLUS)

Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.

There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.

If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.

For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.

For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.

Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.

Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.

Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.

Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.

Paracetamol (Xykaa PLUS) description

Paracetamol (Xykaa PLUS) is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Paracetamol (Xykaa PLUS) exists as small alkaline deliquescent crystals with a saline tasteacinol was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successfulacinol was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic Paracetamol (Xykaa PLUS). Their mode of Paracetamol (Xykaa PLUS) is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.

Paracetamol (Xykaa PLUS) dosage

Usual Adult Paracetamol (Xykaa PLUS) Dose for Fever:

General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.

Paracetamol (Xykaa PLUS) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours

Usual Adult Paracetamol (Xykaa PLUS) Dose for Pain:

General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.

Paracetamol (Xykaa PLUS) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours

Usual Pediatric Dose for Fever:

Oral or Rectal:

<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.

>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)

Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)

>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.

Usual Pediatric Dose for Pain:

Oral or Rectal:

<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.

>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)

Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)

>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.

Paracetamol (Xykaa PLUS) interactions

See also:
What other drugs will affect Paracetamol (Xykaa PLUS)?

With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic Paracetamol (Xykaa PLUS) of Paracetamol (Xykaa PLUS).

With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.

With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Xykaa PLUS).

With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Xykaa PLUS) from the body and may reduce its analgesic Paracetamol (Xykaa PLUS).

With the simultaneous use with urological means reduced their effectiveness.

With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Xykaa PLUS).

When Paracetamol (Xykaa PLUS) applied simultaneously with diazepam may decrease excretion of diazepam.

There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Xykaa PLUS). A case of severe toxic liver injury.

Described cases of toxic effects of Paracetamol (Xykaa PLUS), while the use of isoniazid.

When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Xykaa PLUS), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Xykaa PLUS) and phenobarbital.

In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Xykaa PLUS) may decrease of its absorption.

At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.

With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Xykaa PLUS) and its increased concentration in blood plasma.

When applied simultaneously with probenecid may decrease clearance of Paracetamol (Xykaa PLUS), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Xykaa PLUS) due to increasing its metabolism in the liver.

At simultaneous application of Paracetamol (Xykaa PLUS) with ethinylestradiol increases absorption of Paracetamol (Xykaa PLUS) from the gut.

Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of Paracetamol (Xykaa PLUS) increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).

Paracetamol (Xykaa PLUS) side effects

See also:
What are the possible side effects of Paracetamol (Xykaa PLUS)?

Effects due to the presence of acetylsalicylic acid.

Accidents awareness with respiratory or skin reactions (angioedema, urticaria, asthma, anaphylactic shock);

Cross hypersensitivity reactions with NSAIDs and with tartrazine;

At low doses recommended for the use of Paracetamol (Xykaa PLUS), side effects of aspirin are generally limited to some irritation of the gastro-intestinal tract.

At higher doses, side effects include gastrointestinal mucosal erosions, gastric ulcer or duodenal ulcer, occult blood loss, melena.

Acetylsalicylic acid may also increase the tendency to bleeding and bleeding time (the lengthening of bleeding continues 4-6 days after stopping the drug).

It may also worsen renal function including cases of pre-existing condition (the long-term use can cause chronic kidney disease).

The signs of salicylic overdose described under.

Effects due to the presence of Paracetamol (Xykaa PLUS).

At the doses and duration of recommended treatment, side effects are usually negligible, but the prolonged use of Paracetamol (Xykaa PLUS) in therapeutic doses large (2-4 g per day, or 10-20 tablets Paracetamol (Xykaa PLUS)) may cause the appearance chronic hepatitis. This justifies the recommendations of caution especially in patients with liver disease prior.

Very rarely, it can produce thrombocytopenia.

The acute liver toxicity in overdose massive (doses greater than 8 g of Paracetamol (Xykaa PLUS)) is described in paragraph overdose.

Paracetamol (Xykaa PLUS) contraindications

See also:
What is the most important information I should know about Paracetamol (Xykaa PLUS)?

Paracetamol (Xykaa PLUS) should not be used in patients who have previously exhibited hypersensitivity to aspirin and/or nonsteroidal antiinflammatory agents. Paracetamol (Xykaa PLUS) should not be given to patients with a recent history of gastrointestinal bleeding or in patients with bleeding disorders (e.g., hemophilia).

What is Phenylephrine (Xykaa PLUS)?

Phenylephrine (Xykaa PLUS) (Phenylephrine (Xykaa PLUS)) is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

Phenylephrine (Xykaa PLUS) is used to treat nasal and sinus congestion, or congestion of the tubes that drain fluid from your inner ears, called the eustachian (yoo-STAY-shun) tubes.

Phenylephrine (Xykaa PLUS) may also be used for purposes not listed in this medication guide.

Phenylephrine (Xykaa PLUS) indications

Phenylephrine (Xykaa PLUS) is used for the temporary relief of stuffy nose, sinus, and ear symptoms caused by the common cold, flu, allergies, or other breathing illnesses (e.g., sinusitis, bronchitis). This medication works by decreasing swelling in the nose and ears, thereby lessening discomfort and making it easier to breathe.

Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. Therefore, do not use this product to treat cold symptoms in children younger than 6 years unless specifically directed by the doctor. Some products (such as long-acting tablets/capsules) are not recommended for use in children younger than 12 years. Ask your doctor or pharmacist for more details about using your product safely.

How should I use Phenylephrine (Xykaa PLUS)?

Use Phenylephrine (Xykaa PLUS) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Phenylephrine (Xykaa PLUS).

Uses of Phenylephrine (Xykaa PLUS) in details

Use: Labeled Indications

Hypotension/shock: Treatment of hypotension, vascular failure in shock. Note: Not recommended for routine use in the treatment of septic shock; use should be limited until more evidence demonstrating positive clinical outcomes becomes available (Rhodes 2017).

Guideline recommendations:

Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends Phenylephrine (Xykaa PLUS), if needed, be considered for initial vasoactive management of cardiogenic shock due to aortic stenosis, mitral stenosis, or dynamic left ventricular outflow tract (LVOT) obstruction (AHA [van Diepen 2017]).

Hypotension during anesthesia: As a vasoconstrictor in regional analgesia

Nasal congestion: As a decongestant [OTC]

Off Label Uses

Hypotension in patients with obstructive hypertrophic cardiomyopathy

Phenylephrine (Xykaa PLUS) is a pure alpha1 agonist that will increase systemic vascular resistance without increasing heart rate or contractility. This is advantageous in patients with obstructive hypertrophic cardiomyopathy and hypotension since increases in both heart rate and contractility may cause the obstruction to worsen, leading to a decrease in cardiac output. Other vasopressors like dopamine, epinephrine, and norepinephrine may increase contractility and/or heart rate. Additional trials may be necessary to further define the role of Phenylephrine (Xykaa PLUS) in this condition.

Based on the American Urological Association guidelines for the management of priapism, due to the low risk of cardiovascular side effects intracavernous injection of Phenylephrine (Xykaa PLUS) is recommended for ischemic priapism that persists following aspiration/irrigation.

Phenylephrine (Xykaa PLUS) description

Phenylephrine (Xykaa PLUS) is a sympathomimetic amine that acts predominantly on α-adrenergic receptors. It is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.

Phenylephrine (Xykaa PLUS) dosage

Phenylephrine (Xykaa PLUS) Dosage

Generic name: Phenylephrine (Xykaa PLUS) HYDROCHLORIDE 10mg in 1mL

Dosage form: injection

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

General Dosage and Administration Instructions

Phenylephrine (Xykaa PLUS) (Phenylephrine (Xykaa PLUS) hydrochloride) Injection, 10 mg/mL must be diluted before administration as an intravenous bolus or continuous intravenous infusion to achieve the desired concentration:

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if the solution is colored or cloudy, or if it contains particulate matter. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion.

During Phenylephrine (Xykaa PLUS) administration:

Dosing for Treatment of Hypotension during Anesthesia

The following are the recommended dosages for the treatment of hypotension during anesthesia.

Prepare a 100 mcg/mL Solution for Bolus

Intravenous Administration

For bolus intravenous administration, prepare a solution containing a final concentration of 100 mcg/mL of Phenylephrine (Xykaa PLUS):

Prepare a Solution for Continuous

Intravenous Administration

For continuous intravenous infusion, prepare a solution containing a final concentration of 20 mcg/mL of Phenylephrine (Xykaa PLUS) in 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP:

Directions for Dispensing from Pharmacy Bulk Vial

The Pharmacy Bulk Vial is intended for dispensing of single doses to multiple patients in a pharmacy admixture program and is restricted to the preparation of admixtures for infusion. Each closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set that allows measured dispensing of the contents. The Pharmacy Bulk Vial is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Dispensing from a pharmacy bulk vial should be completed within 4 hours after the vial is penetrated.

More about Phenylephrine (Xykaa PLUS) (Phenylephrine (Xykaa PLUS))

Consumer resources

Professional resources

Related treatment guides

Phenylephrine (Xykaa PLUS) interactions

See also:
What other drugs will affect Phenylephrine (Xykaa PLUS)?

Acetaminophen: May increase the serum concentration of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy

Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. Monitor therapy

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Consider therapy modification

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy

Chloroprocaine: May enhance the hypertensive effect of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy

CloZAPine: May diminish the therapeutic effect of Phenylephrine (Xykaa PLUS) (Systemic). Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Monitor therapy

Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists. Exceptions: Ergoloid Mesylates; Nicergoline. Avoid combination

FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed. Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy

Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Xykaa PLUS) (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of Phenylephrine (Xykaa PLUS). Use of hyaluronidase for other purposes in patients receiving Phenylephrine (Xykaa PLUS) may be considered as clinically indicated. Avoid combination

Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose. Avoid combination

Ioflupane I 123: Phenylephrine (Xykaa PLUS) (Systemic) may diminish the diagnostic effect of Ioflupane I 123. Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors. Refer to linezolid specific monographs for details. Exceptions: Linezolid. Avoid combination

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification

Propacetamol: May increase the serum concentration of Phenylephrine (Xykaa PLUS) (Systemic). Management: Monitor patients closely for increased side effects of Phenylephrine (Xykaa PLUS) if propacetamol is used concomitantly. Patients with underlying blood pressure issues or arrhythmias may need closer monitoring and may warrant consideration of alternative therapies. Monitor therapy

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy

Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists. Monitor therapy

Phenylephrine (Xykaa PLUS) side effects

See also:
What are the possible side effects of Phenylephrine (Xykaa PLUS)?

Applies to Phenylephrine (Xykaa PLUS): intravenous solution

As well as its needed effects, Phenylephrine (Xykaa PLUS) (the active ingredient contained in Phenylephrine (Xykaa PLUS)) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking Phenylephrine (Xykaa PLUS), check with your doctor or nurse immediately:

Incidence not known:

If any of the following symptoms of overdose occur while taking Phenylephrine (Xykaa PLUS), get emergency help immediately:

Symptoms of overdose:

Minor Side Effects

Some Phenylephrine (Xykaa PLUS) side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Incidence not known:

Phenylephrine (Xykaa PLUS) contraindications

See also:
What is the most important information I should know about Phenylephrine (Xykaa PLUS)?

Phenylephrine (Xykaa PLUS) hydrochloride should not be used in patients with severe hypertension, ventricular tachycardia, or in patients who are hypersensitive to it or to any of the components.

Active ingredient matches for Xykaa PLUS:

Caffeine/Chlorpheniramine/Paracetamol/Phenylephrine


List of Xykaa PLUS substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
ALMOLET
ANADECON
AZIREST
B HOLD
B-HOLD (India)
B-HOLD tab 10's (Juggat)$ 0.39
caffeine/chlorpheniramine/paracetamol/phenylephrine (India)
Coristat Tablet
Coristat Tablet (Fervent Life Sciences Pvt Ltd)$ 0.04
COZITUS
COZY PLUS TABLET
CR COLD
CROZY PLUS (India)
200's (Zee Laboratories Ltd)$ 4.34
Crozy Plus Paracetamol 500 mg, Chlorpheniramine 2 mg, Caffeine 15 mg, phenylephrine5 mg. TAB / 200 (Zee Laboratories Ltd)$ 4.34
Crozy Plus 60 ml Syrup (Zee Laboratories Ltd)$ 0.03
CROZY PLUS SYRUP 1 bottle / 50 ML syrup each (Zee Laboratories Ltd)$ 0.39
CROZY PLUS TABLET 1 strip / 10 tablets each (Zee Laboratories Ltd)$ 0.22
CROZY PLUS tab 10's (Zee Laboratories Ltd)$ 0.22
Crozy Plus Paracetamol 500 mg, Chlorpheniramine 2 mg, Caffeine 15 mg, phenylephrine5 mg. TAB / 200 (Zee Laboratories Ltd)$ 4.34
Crozy Plus Syrup (Zee Laboratories Ltd)$ 0.39
CZ PLUS
DECONGIN
DIOMINIC DCA
FEBRIHIST
HATRIC 3 COLD
HATRIC-3 COLD
KOLTUS P TABLET
LAVETA COLD
MAXACOLD
MAXACOLD TABLET 1 strip / 10 tablets each (Unimax)$ 0.16
MAXACOLD tab 10's (Unimax)
NESORYL
New Dolo-Cold Tablet
New Dolo-Cold Tablet (Micro Labs Ltd)$ 0.04
New Instaryl Cold Tablet
New Instaryl Cold Tablet (Aglowmed Drugs Pvt. Ltd.)$ 0.02
NEZA
REMCOLD
REMCOLD TABLET 1 strip / 10 tablets each (Retort Pharma Pvt Ltd)$ 0.25
RUPAR COLD TABLET
Stopross Tablet
Stopross Tablet (Emami Frank Ross Ltd)$ 0.04
YASHCOLD
ZELFAST (India)
10's (Rouzel)
Zelfast Phenylephrine 5 mg, Chlorpheniramine 4 mg, Caffeine 30 mg, Paracetamol500 mg. TAB / 10 (Rouzel)
ZELFAST tab 10's (Rouzel)
Zelfast Phenylephrine 5 mg, Chlorpheniramine 4 mg, Caffeine 30 mg, Paracetamol500 mg. TAB / 10 (Rouzel)

See 42 substitutes for Xykaa PLUS

References

  1. DailyMed. "CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  3. PubChem. "phenylephrine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Xykaa PLUS are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Xykaa PLUS. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


2 consumers reported age

Users%
46-601
50.0%
16-291
50.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

More about Xykaa PLUS

  • Xykaa PLUS generic and brand names

    • Share on Facebook Tweet

    | Privacy Policy
    This site does not supply any medicines. It contains prices for information purposes only.
    © 2003 - 2024 ndrugs.com All Rights Reserved